Sep 20, 2021 / 07:45PM GMT
Matt Biegler - Oppenheimer & Co. Inc. - Analyst
Thanks for joining our next session. My name is Matt Biegler; I'm an analyst on the emerging biotech team here at Oppenheimer. Pleased to introduce our next company, Medicenna, which I'm actually covering with an outperform rating. These guys are developing novel cytokine-based therapies including a novel IL-2 agonist called MDNA11, which you will hear more about.
Just a quick housekeeping note. If you want to ask a question, please type it into the box on the Wall Street Webcasting interface. I think it's at the right-hand side of your screen. So we are joined by CEO, Fahar Merchant. Fahar, the floor is yours.
Fahar Merchant - Medicenna Therapeutics Corp. - President & CEO
Thank you, Matt. Thank you all for joining today's presentation for Medicenna. We will be presenting and putting out some forward-looking statements, so I would encourage you to look at our regulatory filings regarding risk factors, et cetera.
So Medicenna is a company that's really focused on developing and designing
Medicenna Therapeutics Corp at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers